2 / 18
Page 15
Notes:
allied
academies
J Gastroenterol Dig Dis 2017 | Volume 2, Issue 3
World Gastroenterological &
Gastroenterology and Endoscopy
October 30-31, 2017 | Toronto, Canada
World Congress on
Glutathione species and metabolomics prints in subjects with liver disease as biological markers for
the detection of hepatocellular carcinoma
Juan Sanabria
1, 2
1
Marshall University, USA
2
Case Western Reserve University, USA
Background:
The incidence of liver disease is increasing in
USA. Animal models had shown glutathione species in plasma
re ects liver glutathione state and it could be a surrogate for
the detection of hepa-tocellular carcinoma (HCC).
Methods:
The present study aimed to translate methods
to the human and to explore the role of glutathione/
metabolic prints in the progression of liver dysfunction
and in the detection of HCC. Treated plasma from healthy
subjects (n = 20), patients with liver disease (ESLD, n = 99)
and patients after transplantation (LTx, n = 7) were analyzed
by GC- or LC/MS. Glutathione labeling pro le was measured
by isotopomer analyzes of 2H2O enriched plasma. Principal
Component Analyzes (PCA) were used to determined
metabolic prints.
Results:
There was a signi cant difference in glutathione/
metabolic pro les from patients with ESLD vs healthy
subjects and patients after LTx. Similar signi cant differences
were noted on patients with ESLD when strati ed by the
MELD score. PCA analyses showed myristic acid, citric
acid, succinic acid, L-methionine, D-threitol, fumaric acid,
pipecolic acid, isoleucine, hydroxy-butyrate and glycolic,
steraric and hexanoic acids were discriminative metabolites
for ESLD-HCC+ vs ESLD-HCC− subject status.
Conclusions:
Glutathione species and metabolic prints
de ned liver disease severity and may serve as surrogate for
the detection of HCC in patients with established cirrhosis.
Speaker Biography
Juan Sanabria is a Professor of Surgery at Marshall University where he is the Vice-
Chair of the Department and the Scientific Director of the Comprehensive Cancer
Center. He is as well Professor of Nutrition and Preventive Medicine at Case WR
University and he is part of the Metabolomic Core Facility. He has a broad background
in liver pathophysiology, with specific training and expertise in metabolic disturbances
and signatures of the liver in health and disease including non-alcoholic fatty liver
disease and its inflammatory component non-alcoholic steatohepatitis (NASH),
cirrhosis and HCC. At present our groups has developed interventions that prevents
and reverse NASH and cirrhosis, main risk factors for HCC. In addition, he has explored
the significance of liver disease globally, nationally and subnational by my ongoing
collaboration with the global burden of disease group.
e:
sanabriaj@marshall.edu